amminedichloro(2- methylpyridine)platinum(II) (ZD0473)

04/01/2010 - "These studies provide a basis for follow-up clinical studies that would seek to examine the relationship between the anticancer efficacy of picoplatin and expression levels of OCTs and their genetic variants in tumors. "
12/01/2002 - "ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignancies."
12/01/2002 - "In conclusion, ZD0473 appears to have linear pharmacokinetics, and an acceptable tolerability profile at doses up to 120 mg/m2 in Japanese patients with refractory solid malignancies. "
11/01/1997 - "AMD473 is entering Phase I clinical trials under the auspices of the United Kingdom Cancer Research Campaign in 1997."
10/01/2013 - "Picoplatin is expected to overcome tumor resistance in cases which overexpress thiol-conjugating pathways; however, this was not proved in clinical trials. "

12/01/2002 - "This Phase II trial has evaluated the efficacy and tolerability of ZD0473 in second-line ovarian cancer patients. "
12/01/2002 - "A phase II trial of ZD0473 in platinum-pretreated ovarian cancer."
12/01/2002 - "Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval."
12/01/2002 - "In conclusion, ZD0473 has a manageable toxicity profile and encouraging activity in platinum-sensitive ovarian cancer patients."
10/01/2000 - "Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines."

03/01/2004 - "Only the ovarian carcinoma line A2780cp showed resistance to ZD0473 compared to its counterpart A2780S. "
11/01/1997 - "Across the whole panel of cisplatin-sensitive to cisplatin-resistant human ovarian carcinoma xenografts, AMD473 showed improved or at least comparable activity to that observed for an equitoxic dose (4 mg/kg) and schedule of cisplatin. "
03/01/2004 - "For radiosensitization both cisplatin and ZD0473 show additive and subadditive effects in the ovarian carcinoma lines, and additive and superadditive effects in the cervical carcinoma and lung tumour cell lines. "
03/01/2004 - "Whilst all three cell line pairs had one line that was resistant to cisplatin, for ZD0473 the lung tumour HTB56cp and cervical carcinoma ME180 cell lines did not express resistance to their HTB56 and SHA counterparts, respectively. "
01/01/1998 - "AMD473 circumvents resistance in vitro in acquired cisplatin resistant human ovarian carcinoma (HOC) cell line models (2 h SRB assay mean resistance factor = 2.8 +/- 1.2 microM for AMD473, versus 6.5 +/- 3.5 microM for cisplatin). "

10/01/2013 - "This article presents an overview of the pharmacokinetic assessments of picoplatin in lung cancer. "
12/01/2002 - "ZD0473 treatment in lung cancer: an overview of the clinical trial results."
10/01/2013 - "Picoplatin failed to overcome resistance to platinum compounds in lung cancer to achieve significant improved survival of most patients. "
04/01/2010 - "Picoplatin, a third-generation platinum agent, is efficacious against lung cancers that are otherwise resistant or become refractory during platinum treatment. "
10/01/2002 - "These results suggest that ZD0473 may be a potent agent in human lung cancer cells with multifactorial cisplatin resistance."

06/01/2003 - "The results suggest that the combination of ZD0473 with GEM merits further investigation in small cell lung cancer."
06/01/2003 - "We investigated the effects of combinations of ZD0473 with other anticancer drugs on the growth of a human small-cell lung cancer cell line (SBC-3). "
04/20/2009 - "Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer."
06/01/2003 - "In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line."
12/01/2002 - "Three open-label, non-comparative, multicentre Phase II trials have examined the efficacy and tolerability of ZD0473 as first-and second-line therapy in non-small-cell lung cancer (NSCLC) patients and second-line therapy in small-cell lung cancer (SCLC) patients. "